Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
OncoTargets and Therapy2022Vol. Volume 15, pp. 831–836
Citations Over Time
Abstract
This study discovered a novel BAIAP2-ROS1 rearrangement; it provides more knowledge of ROS1 fusion in clinical personalized treatment. The good response to crizotinib therapy emphasizes the importance of DNA-based and RNA-based NGS in rare fusion identification in clinical practice.
Related Papers
- → Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer(2017)258 cited
- → Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies(2020)100 cited
- → Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer(2019)58 cited
- → <p>Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date</p>(2019)17 cited
- → 1262P ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer(2021)1 cited